Evidence

Equivalence of MammaPrint Array Types in Clinical Trials and Diagnostics

March 22, 2016

PUBLICATION: Breast Cancer Res Treat (2016) 156: 279. https://doi.org/10.1007/s10549-016-3764-5 AUTHORS: Inès Beumer, Anke Witteveen, Leonie Delahaye, Diederik Wehkamp, Mireille Snel, Christa Dreezen, John Zheng, Arno Floore, Guido Brink, Bob Chan, Sabine Linn, Rene Bernards, Laura van ’t Veer, Annuska Glas SUMMARY: Here we demonstrate the equivalence and reproducibility of the MammaPrint test on both customized certified array types,…

Read more

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

November 1, 2015

PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Katharine Yao, Robert Goldschmidt, Mary TurkJelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Massimo Cristofanilli SUMMARY: Retrospective, observational study comparing MP+BP subtyping with long-term outcomes: MammaPrint low-risk patients had a 10-year DMFS of 96 % (95 %CI 92.8–99.4), while MammaPrint high-risk patients had a 10-year DMFS of 87%. Read…

Read more

Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis

November 24, 2014

PUBLICATION: Breast Cancer Res Treat (2014) 148: 599. https://doi.org/10.1007/s10549-014-3188-z. AUTHORS: C.A. Drukker, S.G. Elias, M.V. Nijenhuis, J. Wesseling, H. Bartelink, P. Elkhuizen, B. Fowble, P.W. Whitworth, R.R. Patel, F.A. de Snoo, L.J. van ’t Veer, P.D. Beitsch, E.J. Th. Rutgers SUMMARY: After a median follow-up of 8.96 years with 87 LRRs, patients with a high-risk 70-gene signature (n…

Read more

Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms

June 1, 2014

PUBLICATION: Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub 2014 Apr 24. AUTHORS: C.A. Drukker, M.V. Nijenhuis, J.M. Bueno-de-Mesquita, V.P. Retèl, W.H. van Harten, H. van Tinteren, J. Wesseling, M.K. Schmidt, L.J. van’t Veer, G.S. Sonke, E.J. T. Rutgers, M.J. van de Vijver, S.C. Linn SUMMARY: In this cohort, the PREDICT plus tool in combination with the…

Read more

Mammographic Screening Detects Low-Risk Tumor Biology Breast Cancers

February 2, 2014

PUBLICATION: Breast Cancer Res Treat. 2014 Feb;144(1):103-11. doi: 10.1007/s10549-013-2830-5. Epub 2014 Jan 28.7 AUTHORS: Drukker C.A., Schmidt M.K., Rutgers E.J., Cardoso F., Kerlikowske K., Esserman L.J., van Leeuwen F.E., Pijnappel R.M., Slaets L., Bogaerts J., Van’t Veer L.J. SUMMARY: Among the screen-detected cancers, 32 % had a 70-gene signature high-risk and 68 % a low-risk tumor, of which…

Read more

Long-Term Impact of the 70-Gene Signature on Breast Cancer Outcome

February 1, 2014

PUBLICATION: Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21. AUTHORS: Drukker C.A., van Tinteren H., Schmidt M.K., Rutgers E.J., Bernards R., van de Vijver M.J., Van’t Veer L.J. SUMMARY: MammaPrint showed a significant absolute difference in DMFS and OS at 25 years between the patients with a low-risk 70-gene signature (60.4 and 57.3 %…

Read more

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

August 4, 2013

PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Floris H. Groenendijk, Wilbert Zwart, Arno Floore, Stephanie Akbari, Rene Bernards ABSTRACT: It is well established that only estrogen receptor (ER)-positive tumors benefit from hormonal therapies. We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor α (ERα), but fails to respond to hormonal therapy due…

Read more

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

June 12, 2013

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Glück S., de Snoo F., Peeters J., Stork-Sloots L., Somlo G. ABSTRACT: The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in patients with early-stage breast cancer using BluePrint and…

Read more

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

June 1, 2013

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. AUTHORS: Rouzier R., Pronzato P., Chéreau E., Carlson J., Hunt B., Valentine W.J. SUMMARY: Systematic Review: The review identified 29 publications that reported evaluations of two assays: Oncotype DX(®) and MammaPrint. Studies of both tests provided evidence that their routine use was cost saving or…

Read more

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

November 1, 2012

PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub 2012 Sep 8. AUTHORS: Lips E.H., Mukhtar R.A., Yau C., de Ronde J.J., Livasy C., Carey L.A., Loo C.E., Vrancken-Peeters M.J., Sonke G.S., Berry D.A., Van’t Veer L.J., Esserman L.J., Wesseling J., Rodenhuis S., Shelley Hwang E.; I-SPY TRIAL Investigators. SUMMARY: Expression subtyping, particularly the NKI 70-gene signature,…

Read more

Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

June 1, 2012

PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Kondo M., Hoshi S.L., Ishiguro H., Toi M. SUMMARY: The introduction of the assay into Japanese practice of ER+, LN−, HER2− ESBC treatment by including it to Japan’s social health insurance benefit package has a reasonable chance to be judged as cost-effective and may be justified as an…

Read more

Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers

December 2, 2011

PUBLICATION: Breast Cancer Res Treat. 2011 Dec;130(3):725-34. doi: 10.1007/s10549-011-1748-z. Epub 2011 Sep 4. AUTHORS: Esserman L.J., Shieh Y., Rutgers E.J., Knauer M., Retèl V.P., Mook S., Glas A.M., Moore D.H., Linn S., van Leeuwen F.E., van ‘t Veer L.J. SUMMARY:  In women aged 49-60, the time period of diagnosis significantly affects the proportion of cancers that were…

Read more

The Predictive Value of the 70-Gene Signature for Adjuvant Chemotherapy in Early Breast Cancer

March 5, 2010

PUBLICATION: Breast Cancer Res Treat. 2010 Apr;120(3):655-61. doi: 10.1007/s10549-010-0814-2. AUTHORS: Knauer M., Mook S., Rutgers E.J., Bender R.A., Hauptmann M., van de Vijver M.J., Koornstra R.H., Bueno-de-Mesquita J.M., Linn S.C., van ‘t Veer L.J. ABSTRACT: Multigene assays have been developed and validated to determine the prognosis of breast cancer. In this study, we assessed the additional predictive value…

Read more

The 70-gene Signature as a Response Predictor for Neoadjuvant Chemotherapy in Breast Cancer

February 1, 2010

PUBLICATION: Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub 2009 Feb 13. AUTHORS: Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver M.J., Rutgers E.J., Vrancken Peeters M.J., van Tinteren H., Van’t Veer L.J., Rodenhuis S. SUMMARY: 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients…

Read more

Validation of 70-gene Prognosis Signature in Node-Negative Breast Cancer

October 14, 2009

PUBLICATION: Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26. AUTHORS: Bueno-de-Mesquita J.M., Linn S.C., Keijzer R., Wesseling J., Nuyten D.S., van Krimpen C., Meijers C., de Graaf P.W., Bos M.M., Hart A.A., Rutgers E.J., Peterse J.L., Halfwerk H., de Groot R., Pronk A., Floore A.N., Glas A.M., Van’t Veer L.J., van de Vijver…

Read more

The 70-gene Prognosis-Signature Predicts Disease Outcome in Breast Cancer Patients with 1-3 Positive Lymph Nodes in an Independent Validation Study

July 27, 2009

PUBLICATION: Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub 2008 Jul 27. AUTHORS: Mook S., Schmidt M.K., Viale G., Pruneri G., Eekhout I., Floore A., Glas A.M., Bogaerts J., Cardoso F., Piccart-Gebhart M.J., Rutgers E.T., Van’t Veer L.J.; TRANSBIG Consortium. SUMMARY: Among 1-3 LN+ patients, the 10-year distant metastasis-free (DMFS) and breast cancer specific survival (BCSS) probabilities…

Read more